JP2015523365A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015523365A5 JP2015523365A5 JP2015520657A JP2015520657A JP2015523365A5 JP 2015523365 A5 JP2015523365 A5 JP 2015523365A5 JP 2015520657 A JP2015520657 A JP 2015520657A JP 2015520657 A JP2015520657 A JP 2015520657A JP 2015523365 A5 JP2015523365 A5 JP 2015523365A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- membered
- optionally substituted
- item
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 106
- 150000003839 salts Chemical class 0.000 claims description 95
- 239000000203 mixture Substances 0.000 claims description 79
- 239000003814 drug Substances 0.000 claims description 11
- 229940079593 drug Drugs 0.000 claims description 8
- 239000003937 drug carrier Substances 0.000 claims 4
- 125000000217 alkyl group Chemical group 0.000 description 241
- 125000003118 aryl group Chemical group 0.000 description 107
- 125000000623 heterocyclic group Chemical group 0.000 description 103
- 125000004452 carbocyclyl group Chemical group 0.000 description 82
- 229910052736 halogen Inorganic materials 0.000 description 54
- 150000002367 halogens Chemical class 0.000 description 54
- 125000001072 heteroaryl group Chemical group 0.000 description 52
- 125000006708 (C5-C14) heteroaryl group Chemical group 0.000 description 48
- 125000000304 alkynyl group Chemical group 0.000 description 46
- 125000003342 alkenyl group Chemical group 0.000 description 36
- 229910052799 carbon Inorganic materials 0.000 description 35
- 125000004093 cyano group Chemical group *C#N 0.000 description 34
- 125000001188 haloalkyl group Chemical group 0.000 description 33
- 125000002947 alkylene group Chemical group 0.000 description 31
- 125000002619 bicyclic group Chemical group 0.000 description 26
- 125000005843 halogen group Chemical group 0.000 description 26
- 125000003545 alkoxy group Chemical group 0.000 description 24
- 125000004043 oxo group Chemical group O=* 0.000 description 24
- 229910052760 oxygen Inorganic materials 0.000 description 23
- 125000004450 alkenylene group Chemical group 0.000 description 21
- 125000004474 heteroalkylene group Chemical group 0.000 description 21
- 125000000000 cycloalkoxy group Chemical group 0.000 description 20
- 125000006413 ring segment Chemical group 0.000 description 20
- 229910052739 hydrogen Inorganic materials 0.000 description 18
- 229910052757 nitrogen Inorganic materials 0.000 description 15
- 229910052717 sulfur Inorganic materials 0.000 description 13
- 125000005549 heteroarylene group Chemical group 0.000 description 12
- 125000005842 heteroatom Chemical group 0.000 description 12
- 125000001424 substituent group Chemical group 0.000 description 11
- 150000001721 carbon Chemical group 0.000 description 10
- 125000000732 arylene group Chemical group 0.000 description 7
- 125000001153 fluoro group Chemical group F* 0.000 description 7
- 125000004438 haloalkoxy group Chemical group 0.000 description 7
- 125000004433 nitrogen atom Chemical group N* 0.000 description 7
- -1 -OH Chemical group 0.000 description 6
- 241000255925 Diptera Species 0.000 description 6
- 208000010710 hepatitis C virus infection Diseases 0.000 description 6
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 description 5
- HKIOYBQGHSTUDB-UHFFFAOYSA-N folpet Chemical group C1=CC=C2C(=O)N(SC(Cl)(Cl)Cl)C(=O)C2=C1 HKIOYBQGHSTUDB-UHFFFAOYSA-N 0.000 description 5
- 125000004122 cyclic group Chemical group 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 241001385733 Aesculus indica Species 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 125000004419 alkynylene group Chemical group 0.000 description 3
- 125000004429 atom Chemical group 0.000 description 3
- 230000005494 condensation Effects 0.000 description 3
- 238000009833 condensation Methods 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 239000010437 gem Substances 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 3
- 125000004430 oxygen atom Chemical group O* 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 125000004434 sulfur atom Chemical group 0.000 description 3
- 241000162682 Heterogen Species 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 125000000262 haloalkenyl group Chemical group 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 125000006587 (C5-C10) heteroarylene group Chemical group 0.000 description 1
- 101001023866 Arabidopsis thaliana Mannosyl-oligosaccharide glucosidase GCS1 Proteins 0.000 description 1
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229940125977 NS4B inhibitor Drugs 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical class N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 1
- 101800001838 Serine protease/helicase NS3 Proteins 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 125000004980 cyclopropylene group Chemical group 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 238000013160 medical therapy Methods 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261667806P | 2012-07-03 | 2012-07-03 | |
| US61/667,806 | 2012-07-03 | ||
| US201361798524P | 2013-03-15 | 2013-03-15 | |
| US61/798,524 | 2013-03-15 | ||
| PCT/US2013/049119 WO2014008285A1 (en) | 2012-07-03 | 2013-07-02 | Inhibitors of hepatitis c virus |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015220577A Division JP2016041743A (ja) | 2012-07-03 | 2015-11-10 | Ｃ型肝炎ウイルスの阻害剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015523365A JP2015523365A (ja) | 2015-08-13 |
| JP2015523365A5 true JP2015523365A5 (enExample) | 2016-01-07 |
| JP6025977B2 JP6025977B2 (ja) | 2016-11-16 |
Family
ID=48803614
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015520657A Active JP6025977B2 (ja) | 2012-07-03 | 2013-07-02 | Ｃ型肝炎ウイルスの阻害剤 |
| JP2015220577A Withdrawn JP2016041743A (ja) | 2012-07-03 | 2015-11-10 | Ｃ型肝炎ウイルスの阻害剤 |
| JP2018111786A Withdrawn JP2018154651A (ja) | 2012-07-03 | 2018-06-12 | Ｃ型肝炎ウイルスの阻害剤 |
| JP2020085702A Pending JP2020143107A (ja) | 2012-07-03 | 2020-05-15 | Ｃ型肝炎ウイルスの阻害剤 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015220577A Withdrawn JP2016041743A (ja) | 2012-07-03 | 2015-11-10 | Ｃ型肝炎ウイルスの阻害剤 |
| JP2018111786A Withdrawn JP2018154651A (ja) | 2012-07-03 | 2018-06-12 | Ｃ型肝炎ウイルスの阻害剤 |
| JP2020085702A Pending JP2020143107A (ja) | 2012-07-03 | 2020-05-15 | Ｃ型肝炎ウイルスの阻害剤 |
Country Status (40)
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI568722B (zh) | 2012-06-15 | 2017-02-01 | 葛蘭馬克製藥公司 | 作爲ｍＰＧＥＳ－１抑制劑之三唑酮化合物 |
| UA119315C2 (uk) | 2012-07-03 | 2019-06-10 | Гіліад Фармассет Елелсі | Інгібітори вірусу гепатиту с |
| WO2014062196A1 (en) | 2012-10-19 | 2014-04-24 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| US9643999B2 (en) | 2012-11-02 | 2017-05-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| EP2914613B1 (en) | 2012-11-02 | 2017-11-22 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| WO2014071007A1 (en) | 2012-11-02 | 2014-05-08 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| WO2014070974A1 (en) | 2012-11-05 | 2014-05-08 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| PL2950786T3 (pl) | 2013-01-31 | 2020-05-18 | Gilead Pharmasset Llc | Formulacja skojarzona dwóch związków przeciwwirusowych |
| EP2964664B1 (en) | 2013-03-07 | 2017-01-11 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| EA029088B1 (ru) * | 2013-03-15 | 2018-02-28 | Джилид Сайэнс, Инк. | Макроциклические и бициклические ингибиторы вируса гепатита c |
| PL3038601T3 (pl) | 2013-08-27 | 2020-08-24 | Gilead Pharmasset Llc | Formulacja złożona dwóch związków przeciwwirusowych |
| ES2708993T3 (es) * | 2013-12-23 | 2019-04-12 | Gilead Sciences Inc | Formas cristalinas de un tripéptido macrocíclico inhibidor de NS3 del VHC |
| NZ720745A (en) * | 2013-12-23 | 2018-02-23 | Gilead Sciences Inc | Synthesis of a macrocyclic hcv ns3 inhibiting tripeptide |
| US10059969B1 (en) | 2014-10-03 | 2018-08-28 | Abbvie Inc. | Process for the preparation of (S)-2-amino-non-8-enoic acid |
| CN118286245A (zh) | 2014-12-26 | 2024-07-05 | 埃莫里大学 | N4-羟基胞苷和衍生物及与其相关的抗病毒用途 |
| CN107250097B (zh) * | 2015-02-16 | 2020-08-07 | 中央硝子株式会社 | 含氟α-酮羧酸酯类的实用制造方法 |
| WO2017184670A2 (en) | 2016-04-22 | 2017-10-26 | Gilead Sciences, Inc. | Methods for treating zika virus infections |
| EP3455218A4 (en) | 2016-05-10 | 2019-12-18 | C4 Therapeutics, Inc. | C3 CARBON-BASED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION |
| WO2017197036A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Spirocyclic degronimers for target protein degradation |
| WO2017197051A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Amine-linked c3-glutarimide degronimers for target protein degradation |
| EP3454856B1 (en) | 2016-05-10 | 2024-09-11 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
| EA201892375A1 (ru) | 2016-05-27 | 2019-08-30 | Джилид Сайэнс, Инк. | Способы лечения инфекций, вызываемых вирусом гепатита b |
| BR102017011025A2 (pt) | 2016-06-02 | 2017-12-19 | Gilead Pharmasset Llc | Formulation of combination of three antiviral compounds |
| JOP20190052A1 (ar) | 2016-09-22 | 2019-03-21 | Astrazeneca Ab | 5-[2-(بيريدين-2-يلامينو )-3،1 ثيازول-5-يال]-3،2 – ثنائي هيدرو- 1h- إيزوإندول 1--مشتق واحد واستخدامها كمثبطات مزدوجة للدلتا وغاما فوسفاتيديلينوسيتول 3-كيناز |
| MX2019009059A (es) * | 2017-02-01 | 2019-09-16 | Abbvie Inc | Procesos enzimaticos para la preparacion de acido (±)-2-(difluorometil)-1-(alcoxicarbonil)-ciclopropancarboxilico y +acido (±)-2-(vinil)-1-(alcoxicarbonil)-ciclopropancarboxilico. |
| CN110769822A (zh) | 2017-06-20 | 2020-02-07 | C4医药公司 | 用于蛋白降解的n/o-连接的降解决定子和降解决定子体 |
| US11331331B2 (en) | 2017-12-07 | 2022-05-17 | Emory University | N4-hydroxycytidine and derivatives and anti-viral uses related thereto |
| CN111018795B (zh) * | 2019-12-25 | 2023-03-28 | 上海彩迩文生化科技有限公司 | 一种碱性条件下合成喹喔啉-3-酮的方法 |
| US20230218644A1 (en) | 2020-04-16 | 2023-07-13 | Som Innovation Biotech, S.A. | Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus |
| US12083099B2 (en) | 2020-10-28 | 2024-09-10 | Accencio LLC | Methods of treating symptoms of coronavirus infection with viral protease inhibitors |
| EP4382529A1 (en) | 2022-12-07 | 2024-06-12 | Bayer Consumer Care AG | A process for preparing pure (3s)-pyrrolidin-3-ol and pure (3s)-pyrrolidin-3-ol hydrochloride |
Family Cites Families (111)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL155842A0 (en) | 2000-12-12 | 2003-12-23 | Schering Corp | Diaryl peptides as ns3-serine protease inhibitors of hepatitis c virus |
| BR0213562A (pt) | 2001-10-26 | 2004-08-31 | Aventis Pharma Inc | Benzimidazóis e análogos e seu uso como inibidores de cinases de proteìna |
| US6867185B2 (en) | 2001-12-20 | 2005-03-15 | Bristol-Myers Squibb Company | Inhibitors of hepatitis C virus |
| MY140680A (en) | 2002-05-20 | 2010-01-15 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
| DE60324552D1 (en) | 2002-05-20 | 2008-12-18 | Bristol Myers Squibb Co | Substituierte cycloalkyl p1' hepatitis c virus inhibitoren |
| AU2003299519A1 (en) | 2002-05-20 | 2004-05-04 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| DE60334205D1 (en) | 2002-05-20 | 2010-10-28 | Bristol Myers Squibb Co | Heterocyclische sulfonamid-hepatitis-c-virus-hemmer |
| EP2033654B1 (en) | 2003-04-16 | 2012-05-16 | Bristol-Myers Squibb Company | Process for resolving a mixture of alkyl ester enantiomers using an enzyme |
| US7176208B2 (en) | 2003-04-18 | 2007-02-13 | Enanta Pharmaceuticals, Inc. | Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors |
| EP2143727B1 (en) | 2003-04-18 | 2015-01-21 | Enanta Pharmaceuticals, Inc. | Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors |
| ES2297424T3 (es) | 2003-05-21 | 2008-05-01 | Boehringer Ingelheim International Gmbh | Compuestos inhibidores de la hepatitis c. |
| US7135462B2 (en) | 2003-11-20 | 2006-11-14 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| HRP20070043A2 (hr) | 2004-07-16 | 2007-07-31 | Gilead Sciences | Antivirusna sredstva |
| WO2007001406A2 (en) | 2004-10-05 | 2007-01-04 | Chiron Corporation | Aryl-containing macrocyclic compounds |
| EP1879607B1 (en) | 2005-05-02 | 2014-11-12 | Merck Sharp & Dohme Corp. | Hcv ns3 protease inhibitors |
| AR057456A1 (es) | 2005-07-20 | 2007-12-05 | Merck & Co Inc | Inhibidores de la proteasa ns3 del vhc |
| GEP20105124B (en) | 2005-07-25 | 2010-11-25 | Array Biopharma Inc | Novel macrocyclic inhibitors of hepatitis c virus replication |
| PE20070211A1 (es) | 2005-07-29 | 2007-05-12 | Medivir Ab | Compuestos macrociclicos como inhibidores del virus de hepatitis c |
| AU2006275605B2 (en) * | 2005-08-01 | 2011-01-06 | Merck Sharp & Dohme Corp. | Macrocyclic peptides as HCV NS3 protease inhibitors |
| CN101233148A (zh) * | 2005-08-01 | 2008-07-30 | 默克公司 | 作为hcv ns3蛋白酶抑制剂的大环肽 |
| BRPI0617274A2 (pt) | 2005-10-11 | 2011-07-19 | Intermune Inc | compostos e métodos para a inibição de replicação viral de hepatite c |
| US7772183B2 (en) | 2005-10-12 | 2010-08-10 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| GB0609492D0 (en) | 2006-05-15 | 2006-06-21 | Angeletti P Ist Richerche Bio | Therapeutic agents |
| GB0612423D0 (en) | 2006-06-23 | 2006-08-02 | Angeletti P Ist Richerche Bio | Therapeutic agents |
| RU2008152171A (ru) | 2006-07-05 | 2010-08-10 | Интермьюн, Инк. (Us) | Новые ингибиторы вирусной репликации гепатита с |
| EP2076278B1 (en) | 2006-10-24 | 2015-05-06 | Merck Sharp & Dohme Corp. | Macrocyclic HCV NS3 protease inhibitors |
| AU2007309488B2 (en) | 2006-10-24 | 2012-10-11 | Merck Sharp & Dohme Corp. | HCV NS3 protease inhibitors |
| CA2667146C (en) | 2006-10-24 | 2016-01-19 | Merck & Co., Inc. | Hcv ns3 protease inhibitors |
| EP2086982B1 (en) | 2006-10-27 | 2018-08-29 | Merck Sharp & Dohme Corp. | Hcv ns3 protease inhibitors |
| CA2667032A1 (en) | 2006-10-27 | 2008-05-15 | Merck & Co., Inc. | Hcv ns3 protease inhibitors |
| US7888464B2 (en) | 2006-11-16 | 2011-02-15 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US20080287449A1 (en) | 2007-04-26 | 2008-11-20 | Deqiang Niu | Aza-tripeptide hepatitis c serine protease inhibitors |
| WO2008137779A2 (en) | 2007-05-03 | 2008-11-13 | Intermune, Inc. | Novel macrocyclic inhibitors of hepatitis c virus replication |
| MX2009012093A (es) | 2007-05-10 | 2010-01-25 | Intermune Inc | Nuevos peptidos inhibidores de la replicacion del virus de la hepatitis c. |
| US20090005387A1 (en) | 2007-06-26 | 2009-01-01 | Deqiang Niu | Quinoxalinyl macrocyclic hepatitis c virus serine protease inhibitors |
| KR101596524B1 (ko) | 2007-06-29 | 2016-02-22 | 길리애드 사이언시즈, 인코포레이티드 | 항바이러스 화합물 |
| MX2009013830A (es) | 2007-06-29 | 2010-03-01 | Gilead Sciences Inc | Compuestos antivirales. |
| CN101754974B (zh) | 2007-07-19 | 2016-02-03 | Msd意大利有限公司 | 作为抗病毒剂的大环化合物 |
| WO2009014730A1 (en) | 2007-07-26 | 2009-01-29 | Idenix Pharmaceuticals, Inc. | Macrocyclic serine protease inhibitors |
| WO2009042668A2 (en) | 2007-09-24 | 2009-04-02 | Achillion Pharmaceuticals, Inc. | Urea-containing peptides as inhibitors of viral replication |
| WO2009055467A2 (en) | 2007-10-24 | 2009-04-30 | Virobay, Inc. | Compounds that inhibit protease cathepsin s and hcv replication |
| WO2009055335A2 (en) | 2007-10-25 | 2009-04-30 | Taigen Biotechnology Co., Ltd. | Hcv protease inhibitors |
| CL2008003384A1 (es) | 2007-11-14 | 2009-12-11 | Enanta Pharm Inc | Compuestos derivados de quinoxalina macrocíclica, inhibidores de serina proteasa; composicion farmaceutica que los comprende; y su uso en el tratamiento de la hepatitis c. |
| US8030307B2 (en) | 2007-11-29 | 2011-10-04 | Enanta Pharmaceuticals, Inc. | Bicyclic, C5-substituted proline derivatives as inhibitors of the hepatitis C virus NS3 protease |
| WO2009070692A1 (en) | 2007-11-29 | 2009-06-04 | Enanta Pharmaceuticals, Inc. | C5-substituted, proline-derived, macrocyclic hepatitis c serine protease inhibitors |
| CN101932242A (zh) | 2007-12-05 | 2010-12-29 | 益安药业 | 喹喔啉基衍生物 |
| US8273709B2 (en) | 2007-12-14 | 2012-09-25 | Enanta Pharmaceuticals, Inc. | Triazole-containing macrocyclic HCV serine protease inhibitors |
| US8202996B2 (en) | 2007-12-21 | 2012-06-19 | Bristol-Myers Squibb Company | Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide |
| US8309685B2 (en) | 2007-12-21 | 2012-11-13 | Celgene Avilomics Research, Inc. | HCV protease inhibitors and uses thereof |
| US8293705B2 (en) | 2007-12-21 | 2012-10-23 | Avila Therapeutics, Inc. | HCV protease inhibitors and uses thereof |
| JP5755449B2 (ja) | 2007-12-21 | 2015-07-29 | セルジーン アビロミクス リサーチ， インコーポレイテッド | Ｈｃｖプロテアーゼ阻害剤およびその使用 |
| MX2010008109A (es) | 2008-01-24 | 2010-09-22 | Enanta Pharm Inc | Tripéptidos difluorizados como inhibidores de proteasa de serina de virus de hepatitis c (hcv). |
| TW200936131A (en) | 2008-02-04 | 2009-09-01 | Idenix Pharmaceuticals Inc | Macrocyclic serine protease inhibitors |
| CA2714604A1 (en) | 2008-02-25 | 2009-09-03 | Merck Sharp & Dohme Corp. | Macrocyclic hcv ns3 protease inhibitors |
| US8431733B2 (en) | 2008-03-12 | 2013-04-30 | Virobay, Inc. | Process for the preparation of (3S)-3-amino-N-cyclopropyl-2-hydroxyalkanamide derivatives |
| MX2010010276A (es) | 2008-03-20 | 2011-03-25 | Enanta Pharm Inc | Compuestos macrociclicos fluorinados como inhibidores del virus de hepatitis c. |
| CN102046622A (zh) | 2008-04-15 | 2011-05-04 | 因特蒙公司 | 丙型肝炎病毒复制的新颖大环抑制剂 |
| US8163921B2 (en) | 2008-04-16 | 2012-04-24 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| CA2720850A1 (en) | 2008-04-28 | 2009-11-05 | Merck Sharp & Dohme Corp. | Hcv ns3 protease inhibitors |
| WO2009134987A1 (en) | 2008-04-30 | 2009-11-05 | Enanta Pharmaceuticals, Inc. | Difluoromethyl-containing macrocyclic compounds as hepatitis c virus inhibitors |
| KR101313675B1 (ko) * | 2008-07-22 | 2013-10-02 | 이스티투토 디 리세르쉐 디 비올로지아 몰레콜라레 피. 안젤레티 에스.알.엘. | Ｈｃｖ ｎｓ3 프로테아제 억제제로서의 마크로사이클릭 퀴녹살린 화합물 |
| BRPI0916609A2 (pt) | 2008-08-07 | 2015-08-04 | Hoffmann La Roche | Processo para a preparação de um macrociclo |
| EP2334680A2 (en) | 2008-08-20 | 2011-06-22 | Sequoia Pharmaceuticals, Inc. | Hcv protease inhibitors |
| UY32099A (es) | 2008-09-11 | 2010-04-30 | Enanta Pharm Inc | Inhibidores macrocíclicos de serina proteasas de hepatitis c |
| BRPI0918513A2 (pt) | 2008-09-16 | 2015-12-01 | Boehringer Ingelheim Int | formas cristalinas de um derivado de 2-tiazolil-4-quinolinil-óxi, seu sal de sódio, suas composições farmacêuticas e seu uso |
| WO2010033466A1 (en) | 2008-09-16 | 2010-03-25 | Phenomix Corporation | Macrocyclic inhibitors of hepatitis c protease |
| US20100080770A1 (en) | 2008-09-29 | 2010-04-01 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| US8044087B2 (en) | 2008-09-29 | 2011-10-25 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8563505B2 (en) | 2008-09-29 | 2013-10-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| CA2740728A1 (en) | 2008-10-15 | 2010-04-22 | Intermune, Inc. | Therapeutic antiviral peptides |
| WO2010048468A1 (en) | 2008-10-23 | 2010-04-29 | Concert Pharmaceuticals, Inc. | Deuterated macrocyclic inhibitors of viral ns3 protease |
| AU2009316472B2 (en) | 2008-11-20 | 2015-07-09 | Achillion Pharmaceuticals, Inc. | Cyclic carboxamide compounds and analogues thereof as of Hepatitis C virus |
| EA022272B1 (ru) | 2008-11-21 | 2015-12-30 | Бёрингер Ингельхайм Интернациональ Гмбх | Фармацевтическая композиция эффективного ингибитора всг для перорального введения |
| US20100272674A1 (en) | 2008-12-04 | 2010-10-28 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| CN102245598B (zh) | 2008-12-10 | 2014-01-29 | 艾其林医药公司 | 病毒复制抑制剂4-氨基-4-氧代丁酰基肽环状类似物 |
| US8283310B2 (en) | 2008-12-15 | 2012-10-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| WO2010080389A1 (en) | 2008-12-19 | 2010-07-15 | Gilead Sciences, Inc. | Hcv ns3 protease inhibitors |
| MX2011006764A (es) | 2008-12-23 | 2011-08-03 | Ortho Mcneil Janssen Pharm | Procedimiento y compuestos intermedios para preparar un inhibidor de proteasa macrociclico del vhc. |
| WO2010132163A1 (en) | 2009-05-13 | 2010-11-18 | Enanta Pharmaceuticals, Inc. | Macrocyclic compounds as hepatitis c virus inhibitors |
| EP2432318A4 (en) | 2009-05-22 | 2012-11-21 | Sequoia Pharmaceuticals Inc | NS3 PROTEASE INHIBITORS OF BIPACROCYCLIC HEPATITIS C VIRUS |
| EP2459582B1 (en) | 2009-07-30 | 2015-05-27 | Merck Sharp & Dohme Corp. | Hepatitis c virus ns3 protease inhibitors |
| JP2013500961A (ja) | 2009-07-31 | 2013-01-10 | カディラ ヘルスケア リミテッド | グルコキナーゼ（ｇｋ）アクチベーターとしての置換ベンズアミド誘導体 |
| CN102470158A (zh) | 2009-08-27 | 2012-05-23 | 默沙东公司 | 制备丙型肝炎病毒的蛋白酶抑制剂的工艺方法 |
| CN105001302A (zh) | 2009-09-28 | 2015-10-28 | 英特穆恩公司 | C型肝炎病毒复制的环肽抑制剂 |
| TW201116540A (en) | 2009-10-01 | 2011-05-16 | Intermune Inc | Therapeutic antiviral peptides |
| WO2011049908A2 (en) | 2009-10-19 | 2011-04-28 | Enanta Pharmaceuticals, Inc. | Bismacrokyclic compounds as hepatitis c virus inhibitors |
| CN103118681B (zh) | 2010-03-10 | 2015-02-18 | 艾伯维巴哈马有限公司 | 固体组合物 |
| US8530497B2 (en) | 2010-03-11 | 2013-09-10 | Boehringer Ingelheim International Gmbh | Crystalline salts of a potent HCV inhibitor |
| TW201211046A (en) | 2010-06-07 | 2012-03-16 | Enanta Pharm Inc | Macrocyclic hepatitis C serine protease inhibitors |
| WO2012019299A1 (en) | 2010-08-11 | 2012-02-16 | Boehringer Ingelheim International Gmbh | Hepatitis c inhibitor compounds |
| WO2012037259A1 (en) | 2010-09-15 | 2012-03-22 | Intermune, Inc. | Novel inhibitors of hepatitis c virus replication |
| WO2012040040A1 (en) | 2010-09-21 | 2012-03-29 | Merck Sharp & Dohme Corp. | Hcv ns3 protease inhibitors |
| KR101894704B1 (ko) * | 2010-09-21 | 2018-09-05 | 이난타 파마슈티칼스, 인코포레이티드 | 매크로사이클릭 프롤린 유도된 ｈｃｖ 세린 프로테아제 억제제 |
| US20120095211A1 (en) | 2010-09-22 | 2012-04-19 | Intermune, Inc. | Substituted proline inhibitors of hepatitis c virus replication |
| WO2012047764A1 (en) | 2010-10-04 | 2012-04-12 | Intermune, Inc. | Therapeutic antiviral peptides |
| WO2012054874A1 (en) | 2010-10-22 | 2012-04-26 | Intermune, Inc. | Novel macrocyclic inhibitors of hepatitis c virus replication |
| WO2012061248A2 (en) | 2010-11-01 | 2012-05-10 | Rfs Pharma, Llc | Novel specific hcv ns3 protease inhibitors |
| WO2012082672A2 (en) | 2010-12-14 | 2012-06-21 | Merck Sharp & Dohme Corp. | Process and intermediates for preparing macrolactams |
| WO2012092411A2 (en) | 2010-12-30 | 2012-07-05 | Enanta Pharmaceuticals, Inc. | Phenanthridine macrocyclic hepatitis c serine protease inhibitors |
| JP2014502620A (ja) | 2010-12-30 | 2014-02-03 | エナンタ ファーマシューティカルズ インコーポレイテッド | 大環状ｃ型肝炎セリンプロテアーゼ阻害剤 |
| US8957203B2 (en) | 2011-05-05 | 2015-02-17 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| WO2012166459A1 (en) | 2011-05-27 | 2012-12-06 | Bristol-Myers Squibb Company | Tripeptides incorporating deuterium as inhibitors of hepatitis c virus |
| US8691757B2 (en) | 2011-06-15 | 2014-04-08 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| WO2012171332A1 (zh) | 2011-06-16 | 2012-12-20 | 爱博新药研发(上海)有限公司 | 抑制丙型肝炎病毒的大环状杂环化合物及其制备和应用 |
| US8912141B2 (en) | 2011-06-23 | 2014-12-16 | Panmed Ltd. | Treatment of hepatitis C virus |
| KR20140053330A (ko) | 2011-08-19 | 2014-05-07 | 머크 샤프 앤드 돔 코포레이션 | 마크로락탐의 제조를 위한 방법 및 중간체 |
| JP2015513520A (ja) | 2011-10-31 | 2015-05-14 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | ウイルス疾患の治療に有用な組成物 |
| EP2780026B1 (en) | 2011-11-15 | 2019-10-23 | Merck Sharp & Dohme Corp. | Hcv ns3 protease inhibitors |
| JP2015503616A (ja) | 2012-01-12 | 2015-02-02 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 強力なｈｃｖ阻害薬の安定化医薬製剤 |
| UA119315C2 (uk) | 2012-07-03 | 2019-06-10 | Гіліад Фармассет Елелсі | Інгібітори вірусу гепатиту с |
| EA029088B1 (ru) | 2013-03-15 | 2018-02-28 | Джилид Сайэнс, Инк. | Макроциклические и бициклические ингибиторы вируса гепатита c |
-
2013
- 2013-02-07 UA UAA201413651A patent/UA119315C2/uk unknown
- 2013-07-02 RS RS20190303A patent/RS58409B1/sr unknown
- 2013-07-02 ES ES13739324.5T patent/ES2605383T3/es active Active
- 2013-07-02 WO PCT/US2013/049119 patent/WO2014008285A1/en not_active Ceased
- 2013-07-02 CN CN201610474633.5A patent/CN106117309B/zh active Active
- 2013-07-02 HR HRP20161379TT patent/HRP20161379T1/hr unknown
- 2013-07-02 EP EP20191299.5A patent/EP3825312A1/en not_active Withdrawn
- 2013-07-02 SM SM20160470T patent/SMT201600470T1/it unknown
- 2013-07-02 MX MX2014015846A patent/MX360597B/es active IP Right Grant
- 2013-07-02 SG SG10201912269YA patent/SG10201912269YA/en unknown
- 2013-07-02 PT PT16190694T patent/PT3159345T/pt unknown
- 2013-07-02 DK DK16190694.6T patent/DK3159345T3/en active
- 2013-07-02 HU HUE13739324A patent/HUE032404T2/en unknown
- 2013-07-02 SM SM20190167T patent/SMT201900167T1/it unknown
- 2013-07-02 PT PT137393245T patent/PT2870160T/pt unknown
- 2013-07-02 AU AU2013286729A patent/AU2013286729B2/en active Active
- 2013-07-02 UY UY0001034888A patent/UY34888A/es not_active Application Discontinuation
- 2013-07-02 SG SG11201408739VA patent/SG11201408739VA/en unknown
- 2013-07-02 KR KR1020197031860A patent/KR20190124346A/ko not_active Withdrawn
- 2013-07-02 US US14/412,331 patent/US20150175655A1/en not_active Abandoned
- 2013-07-02 EA EA201790661A patent/EA033961B1/ru unknown
- 2013-07-02 ME MEP-2016-245A patent/ME02547B/me unknown
- 2013-07-02 MY MYPI2014003617A patent/MY173342A/en unknown
- 2013-07-02 EA EA201492214A patent/EA027390B1/ru unknown
- 2013-07-02 CA CA2877005A patent/CA2877005C/en active Active
- 2013-07-02 PL PL13739324T patent/PL2870160T3/pl unknown
- 2013-07-02 EP EP13739324.5A patent/EP2870160B1/en active Active
- 2013-07-02 DK DK13739324.5T patent/DK2870160T3/en active
- 2013-07-02 PE PE2014002587A patent/PE20150204A1/es active IP Right Grant
- 2013-07-02 HU HUE16190694A patent/HUE042345T2/hu unknown
- 2013-07-02 ES ES16190694T patent/ES2716138T3/es active Active
- 2013-07-02 EP EP16190694.6A patent/EP3159345B1/en active Active
- 2013-07-02 BR BR122021012378-0A patent/BR122021012378B1/pt active IP Right Grant
- 2013-07-02 MD MDA20180040A patent/MD20180040A2/ro not_active Application Discontinuation
- 2013-07-02 SI SI201330345A patent/SI2870160T1/sl unknown
- 2013-07-02 JP JP2015520657A patent/JP6025977B2/ja active Active
- 2013-07-02 RS RS20161182A patent/RS55494B1/sr unknown
- 2013-07-02 KR KR1020167008636A patent/KR102040023B1/ko active Active
- 2013-07-02 NZ NZ703064A patent/NZ703064A/en unknown
- 2013-07-02 ES ES18215386T patent/ES2827300T3/es active Active
- 2013-07-02 KR KR1020147037149A patent/KR101610575B1/ko active Active
- 2013-07-02 MD MDA20140136A patent/MD4602B1/ro not_active IP Right Cessation
- 2013-07-02 LT LTEP16190694.6T patent/LT3159345T/lt unknown
- 2013-07-02 US US13/934,090 patent/US9296782B2/en active Active
- 2013-07-02 EP EP18215386.6A patent/EP3492464B1/en active Active
- 2013-07-02 IN IN2598MUN2014 patent/IN2014MN02598A/en unknown
- 2013-07-02 AP AP2014008166A patent/AP3903A/en active
- 2013-07-02 AR ARP130102368 patent/AR091661A1/es active IP Right Grant
- 2013-07-02 ME MEP-2019-66A patent/ME03362B/me unknown
- 2013-07-02 CN CN201380042756.6A patent/CN104540832B/zh active Active
- 2013-07-02 NZ NZ739248A patent/NZ739248A/en unknown
- 2013-07-02 PL PL16190694T patent/PL3159345T3/pl unknown
- 2013-07-02 LT LTEP13739324.5T patent/LT2870160T/lt unknown
- 2013-07-02 SG SG10201702950TA patent/SG10201702950TA/en unknown
- 2013-07-02 BR BR112014033080-8A patent/BR112014033080B1/pt active IP Right Grant
- 2013-07-02 TW TW102123626A patent/TWI602822B/zh active
- 2013-07-02 SI SI201331350T patent/SI3159345T1/sl unknown
-
2014
- 2014-12-22 PH PH12014502862A patent/PH12014502862B1/en unknown
- 2014-12-28 IL IL236500A patent/IL236500B/en active IP Right Grant
- 2014-12-31 CL CL2014003634A patent/CL2014003634A1/es unknown
-
2015
- 2015-01-13 CO CO15005727A patent/CO7160104A2/es unknown
- 2015-01-20 EC ECIEPI20152066A patent/ECSP15002066A/es unknown
- 2015-02-03 CR CR20150045A patent/CR20150045A/es unknown
- 2015-11-10 JP JP2015220577A patent/JP2016041743A/ja not_active Withdrawn
-
2016
- 2016-01-13 AU AU2016200201A patent/AU2016200201A1/en not_active Abandoned
- 2016-01-15 US US14/996,961 patent/US20160130300A1/en not_active Abandoned
- 2016-02-03 AU AU2016200670A patent/AU2016200670A1/en not_active Abandoned
- 2016-06-17 US US15/185,273 patent/US9655944B2/en active Active
- 2016-10-12 PH PH12016502040A patent/PH12016502040A1/en unknown
- 2016-12-22 CY CY20161101337T patent/CY1118379T1/el unknown
- 2016-12-27 SM SM201600470T patent/SMT201600470B/it unknown
-
2017
- 2017-04-14 US US15/488,035 patent/US20170290827A1/en not_active Abandoned
- 2017-05-23 IL IL252446A patent/IL252446A0/en active IP Right Grant
- 2017-06-13 AU AU2017203984A patent/AU2017203984B2/en active Active
-
2018
- 2018-06-11 US US16/005,111 patent/US10335409B2/en active Active
- 2018-06-12 JP JP2018111786A patent/JP2018154651A/ja not_active Withdrawn
- 2018-09-04 IL IL26158118A patent/IL261581B/en active IP Right Grant
- 2018-11-08 MX MX2018013668A patent/MX2018013668A/es unknown
-
2019
- 2019-03-19 CY CY20191100328T patent/CY1121418T1/el unknown
- 2019-03-25 HR HRP20190578TT patent/HRP20190578T1/hr unknown
- 2019-05-10 US US16/409,610 patent/US10603318B2/en active Active
- 2019-08-29 AU AU2019222909A patent/AU2019222909B2/en active Active
- 2019-09-25 IL IL26966219A patent/IL269662A/en unknown
-
2020
- 2020-05-04 PH PH12020550552A patent/PH12020550552A1/en unknown
- 2020-05-15 JP JP2020085702A patent/JP2020143107A/ja active Pending
-
2021
- 2021-06-23 AU AU2021204238A patent/AU2021204238A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015523365A5 (enExample) | ||
| CN102239164B (zh) | 2h-色烯化合物及其衍生物 | |
| JP2012513479A5 (enExample) | ||
| CN104136433B (zh) | 具有杂三环部分的抗病毒化合物 | |
| RU2016150326A (ru) | Производные изоиндолина для применения в лечении вирусной инфекции | |
| JP2011518835A5 (enExample) | ||
| JP2013056886A5 (enExample) | ||
| JP2010518128A (ja) | Ｃ型肝炎ｎｓ３プロテアーゼのインヒビター | |
| JP2014503516A5 (enExample) | ||
| JP2017526730A (ja) | Ｔｏｌｌ様受容体モジュレーターの固体形態 | |
| JP2007532474A5 (enExample) | ||
| IL170894A (en) | Antiviral phosphonate analogs | |
| JP2013514359A5 (enExample) | ||
| JP2012517444A5 (enExample) | ||
| RU2011141559A (ru) | Ингибиторы серинпротеазы | |
| MY154683A (en) | Pharmaceutical composition for a hepatitis c viral protease inhibitor | |
| TW201116540A (en) | Therapeutic antiviral peptides | |
| EA201270144A1 (ru) | Комбинированная терапия при лечении диабета | |
| JP2006507220A5 (enExample) | ||
| JP2015522018A5 (enExample) | ||
| RU2014139825A (ru) | Производные ингенола для реактивации латентного вируса вич | |
| JP2010505865A5 (enExample) | ||
| EA200701324A1 (ru) | Соединения пиридина для лечения заболеваний, опосредованных действием простагландина | |
| RU2017103656A (ru) | Производные изоиндолинона, полезные в качестве противовирусных средств | |
| RU2016151973A (ru) | Пиридиноны, замещенные фенилом и трет-бутилуксусной кислотой, обладающие анти-вич эффектами |